Spain’s credit rating upgraded to ’A+’ by S&P on strong growth
Investing.com -- CAMP4 Therapeutics Corporation (NASDAQ:CAMP) stock surged 200% following the announcement of an oversubscribed private placement that could raise up to $100 million to advance its first-in-class treatment for SYNGAP1-related disorders.
The clinical-stage biopharmaceutical company secured $50 million in upfront proceeds through the sale of common stock priced at $1.53 per share and pre-funded warrants. CAMP4 could receive an additional $50 million upon achieving specific milestones, including regulatory clearance to initiate a Phase 1/2 clinical trial for its SYNGAP1 development candidate, expected to begin as early as the second half of 2026.
"With this financing we are well positioned to bring a potential first-in-class treatment for SYNGAP1-related disorders into the clinic," said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4.
The private placement was led by new investor Coastlands Capital, with participation from Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners, and the SynGAP Research Fund. Leerink Partners served as the lead placement agent.
Alongside the financing, CAMP4 announced key leadership changes. Doug Williams, Ph.D., who joined the board in March 2025, will become Board Chair, while Daniel Tardiff, Ph.D., has been elevated to Chief Scientific Officer effective October 1, 2025.
CAMP4 Therapeutics focuses on developing regulatory RNA-targeting therapeutics designed to upregulate gene expression to restore healthy protein levels in patients with genetic diseases. The company intends to use the proceeds to fund the preclinical and clinical development of its SYNGAP1 program, working capital, and general corporate purposes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.